Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields

Published 11/04/2024, 12:48
Updated 11/04/2024, 14:40
© Reuters.  Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Pfizer Inc. (NYSE: PFE)

  • Dividend Yield: 6.38%
  • Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on April 5, 2024. This analyst has an accuracy rate of 64%.
  • Guggenheim analyst Vamil Divan initiated coverage on the stock with a Buy rating and a price target of $36 on Feb. 23, 2024. This analyst has an accuracy rate of 77%.
  • Recent News: Pfizer recently released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial,evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
GSK plc
  • Dividend Yield: 3.61%
  • BMO Capital analyst Etzer Darout maintained an Outperform rating and cut the price target from $82 to $80 on Feb. 12, 2024. This analyst has an accuracy rate of 60%.
  • Morgan Stanley analyst Mark Purcell initiated coverage on the stock with an Overweight rating and a price target of $85 on Jan. 23, 2024. This analyst has an accuracy rate of 65%.
  • Recent News: CureVac released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Patterson Companies, Inc.
  • Dividend Yield: 4.05%
  • Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and slashed the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 78%.
  • Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 79%.
  • Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.

Read More: Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.